ModGene gets patent in Alzheimer’s prevention push

ModGene Pharma, LLC announced the issuance of a US patent entitled “Compositions and Methods for Reduction of Amyloid-beta Load” with the claims covering the use of an “imatinib-related compound for reduction of amyloid-β production in Alzheimer’s disease.”

ModGene Pharma CEO Greg Sutcliffe said: “This patent allowance is a very significant milestone as it supports our unique approach to Alzheimer’s disease prevention and expands our intellectual property portfolio.

“We are the first to have identified a ‘statin’-type approach to Alzheimer’s prevention that utilizes compounds that can be investigated in clinical trials relatively soon.”